The Effectiveness of Packaged Medicine in Eradication Therapy of Helicobacter pylori in Japan

• Kawai Takashi

  Endoscopy Center, Tokyo Medical University Hospital

• Kawakami Kohei

  Endoscopy Center, Tokyo Medical University Hospital

• Kataoka Mikinori

  Endoscopy Center, Tokyo Medical University Hospital

• Takei Kazuo

  Endoscopy Center, Tokyo Medical University Hospital

• Taira Satoru

  Fourth Department of Internal Medicine, Tokyo Medical University

• Itoi Takao

  Fourth Department of Internal Medicine, Tokyo Medical University

• Moriyasu Fuminori

  Fourth Department of Internal Medicine, Tokyo Medical University

• Takagi Yuu

  Third Department of Surgery, Tokyo Medical University

• Aoki Tatsuya

  Third Department of Surgery, Tokyo Medical University

• Matsubayasiu Jun

  Division of Pathology, Tokyo Medical University Hospital

• Mukai Kiyoshi

  Division of Pathology, Tokyo Medical University Hospital

• Rimbara Emiko

  Department of Pathogenic Microbiology, Tokyo University of Pharmacology and Pharmacy

• Noguchi Norihisa

  Department of Pathogenic Microbiology, Tokyo University of Pharmacology and Pharmacy

• Sasatsu Masanori

  Department of Pathogenic Microbiology, Tokyo University of Pharmacology and Pharmacy

抄録

Helicobacter pylori (H. pylori) eradication therapy for peptic ulcers is performed at many facilities in Japan. The eradication regimens are consisted of the 7-day triple therapy using lansoprazole (LPZ) or omeprazole (OPZ) + amoxicillin (AMPC) + clarithromycin (CAM). In theses regimens, 2 types of antibacterial drug are included, the method of taking medicine has been problematic. In this study, we evaluated the usefulness of a packaged tablets and capsules that contain eradication drugs. (Product name: Lansap). Subjects and methods: The study was performed in 100 H. pylori positive patients with upper gastrointestinal disease. The regimen of the eradicating drugs was administration for 7 days of LPZ 60 mg + AMPC 1,500 mg + CAM 800 mg. The patients were randomly divided into two groups. One group was prescribed a package sets of tablets/capsules (package group) for taking the regimen, second group were prescribed the tablets/capsules from separate sets (conventional group) for taking the drugs. Eradication was evaluated by ¹³C urea breath test 6–8 weeks after completion of the treatment. A questionnaire survey was also performed immediately after completion of the treatment regarding to forgetting to take the medicine, mistaking the dosage (quantity) of medicine, the total dose of medicine, and understanding of adverse effects of drugs. Results: The eradication rate (ITT) was 68.0% in the package group and 72.0% in the conventional group, showing no significant difference. Three and 7 patients forgot to take some drugs in the package and conventional groups, respectively, showing no significant difference. None and 2 patients mistook the dosage of medicine respectively. 29 and 26 patients felt that the total dose too much, respectively. As for understanding of adverse effects of drug, 24 and 25 patients understood them respectively. Conclusion: In H. pylori eradication therapy, package sets of eradication medicine are useful for prevention of mistaking the dosage of medicine.<br>

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　ａｎｄ　Ｎｕｔｒｉｔｉｏｎ

  Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　ａｎｄ　Ｎｕｔｒｉｔｉｏｎ 38 (2), 73-76, 2006

  一般社団法人　日本酸化ストレス学会

キーワード

• <i>Helicobacter pylori</i>
• eradication
• package set

詳細情報

• CRID: 1390282679649924608
• NII論文ID: 130004466451
• DOI: 10.3164/jcbn.38.73
• ISSN: 18805086
• ISSN: 09120009
• Web Site: https://search.jamas.or.jp/link/ui/2007002802
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可